Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

Dow, S&P 500 and Nasdaq Shake Off Government Shutdown to Trade Higher

Stocks turn higher on Monday, as investors watch for the impact of a federal government shutdown that entered its third day.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Juno Therapeutics, Inc. To Celgene Corp. Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Juno Therapeutics, Inc. To Celgene Corp. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Juno Therapeutics, Inc.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

Will the Government Shutdown Kill the Mind-Blowing Bull Market?

The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.

The Government Shutdown May Actually Be a Positive for the Stock Market

The Government Shutdown May Actually Be a Positive for the Stock Market

There are 5 key factors that will impact stocks this week.

Celgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics

Celgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics

Celgene inks the Summit, N.J.-based group's biggest-ever takeover with a $9 billion play for cancer treatment specialist biotech Juno Therapeutics.

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

Shutdown Enters Day 3, Sanofi Buys Bioverativ - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.

Celgene Corporation To Acquire Juno Therapeutics, Inc., Advancing Global Leadership In Cellular Immunotherapy

Celgene Corporation To Acquire Juno Therapeutics, Inc., Advancing Global Leadership In Cellular Immunotherapy

Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.

Celgene Could Be Bulking Up Very Fast

Celgene Could Be Bulking Up Very Fast

The biopharmaceutical company, whose biggest acquisition to date was Receptos in 2015 for $7.2 billion, recently agreed to pay up to $7 billion for Impact Biomedicines and reportedly is in talks for Juno, an immunotherapy company.

Dow Soars 322 Points to New Record, Exploding Past 26,000

Dow Soars 322 Points to New Record, Exploding Past 26,000

The Dow, S&P 500 and Nasdaq all finished at new records on Wednesday.

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

I've added to my positions in these names on yesterday's intraday silliness.

Stocks Rebound Despite Financial Sector Weakness

Stocks Rebound Despite Financial Sector Weakness

Stocks on Wall Street rebound Wednesday despite weakness in the financial sector.

A Pause That Refreshes, Not a Signal to Be Bearish on Market

A Pause That Refreshes, Not a Signal to Be Bearish on Market

The bears may sound smart, but they remain toothless.

Bank of America, Goldman Sachs, Juno and Ford - 5 Things You Must Know

Bank of America, Goldman Sachs, Juno and Ford - 5 Things You Must Know

U.S. stock futures are rising Wednesday, suggesting Wall Street will rebound from the previous session when the Dow broke through 26,000 for the first time but ended the day with a small loss.

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin maintains its decline while U.S. stock futures suggest a rebound from yesterday's small loss. Are you ready for today's trading?

Deal Buzz Sends Juno Shares Soaring

Deal Buzz Sends Juno Shares Soaring

Shares of the biotech firm jumped in after-hours trading on the heels of a report that Celgene was in discussions to acquire the company.

Juno Therapeutics Names Cindy Elkins As Chief Information Officer

Juno Therapeutics Names Cindy Elkins As Chief Information Officer

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Cindy Elkins as Chief Information...

Juno Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Juno Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 36 th Annual J.

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Juno Therapeutics Highlights Data And Presentations Supporting Best-in-Class Strategy For JCAR017 At ASH

Juno Therapeutics Highlights Data And Presentations Supporting Best-in-Class Strategy For JCAR017 At ASH

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American...

Juno Therapeutics And Celgene Corporation Release Additional Data From TRANSCEND Trial Of JCAR017 In Patients With Relapsed Or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Juno Therapeutics And Celgene Corporation Release Additional Data From TRANSCEND Trial Of JCAR017 In Patients With Relapsed Or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation (NASDAQ: CELG) today released additional data from the...

Juno Therapeutics Highlights Key Translational Insights With JCAR017 In Patients With DLBCL

Juno Therapeutics Highlights Key Translational Insights With JCAR017 In Patients With DLBCL

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented new translational insights on clinical outcomes with its...

Juno Therapeutics Signs Licensing Agreements With Lilly, OncoTracker, And Fred Hutchinson Cancer Research Center To Advance Its BCMA-Directed Engineered T Cell Program In Multiple Myeloma With Gamma Secretase Inhibition

Juno Therapeutics Signs Licensing Agreements With Lilly, OncoTracker, And Fred Hutchinson Cancer Research Center To Advance Its BCMA-Directed Engineered T Cell Program In Multiple Myeloma With Gamma Secretase Inhibition

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple...

Juno Therapeutics Appoints Ann L. Lee As Executive Vice President Of Technical Operations And Patrick Y. Yang As Executive Vice President, Senior Advisor To The CEO

Juno Therapeutics Appoints Ann L. Lee As Executive Vice President Of Technical Operations And Patrick Y. Yang As Executive Vice President, Senior Advisor To The CEO

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Ann L.

Juno Therapeutics Has a Great Setup

Juno Therapeutics Has a Great Setup

Institutions are piling into Juno Therapeutics.

Chart of the Day: Juno

Institutions are piling into Juno Therapeutics.

Juno Therapeutics To Present At November 2017 Investor Conferences

Juno Therapeutics To Present At November 2017 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in November.

Juno Therapeutics Reports Third Quarter 2017 Financial Results

Juno Therapeutics Reports Third Quarter 2017 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the third quarter...